Through functional analysis, we have confirmed that TNS4 is significantly downregulated by cetuximab in a subset of colorectal cancer cell lines including KRAS activating mutations, suggesting that TNS4 may be one of the pharmacological targets of cetuximab. Here, TNS4 is linked to colorectal cancer.